Skip to main content
Top

Comparative Study of [18F]DPA714 and [18F]FDG PET Tracers in an Experimental Model of Pulmonary Tuberculosis

Published in:

Abstract

Purpose

Tuberculosis (TB) continues to afflict global health. Therefore, a deeper understanding of the host response mechanisms that underly pathogenesis versus disease control upon infection with Mycobacterium tuberculosis (Mtb) is required to leverage the development of improved therapeutic or prophylactic TB treatment regimens. In the present work positron emission tomography (PET) using [18F]DPA714 is piloted as a tracer of the mitochondrial translocator protein TSPO that mainly targets macrophages.

Procedures

We compared two tracers: [18F]DPA714 to the widely applied marker [18F]FDG to visualize the development of experimental pulmonary TB in three rhesus monkeys (Macaca mulatta), that were infected with Mtb by repeated low dose exposure. Next to baseline recordings prior to infectious challenge, two PETs at a two-weeks interval were acquired early after the manifestation of TB infection for each of the respective tracers.

Results & Conclusions

Here, we demonstrate that both PET tracers detected Mtb infection. The inflammatory response tracked by [18F]FDG progressively increased in line with the developing TB pathology, while [18F]DPA714 showed a transient signal in lungs and lung-draining hilar lymph nodes. This study underpins the potential value of different tracers to investigate cellular and molecular host response cascades in experimental medicine settings, in this case, into a (transient) local involvement of myeloid immune cell activation versus inflammation-associated glucose consumption in pulmonary TB.
Title
Comparative Study of [18F]DPA714 and [18F]FDG PET Tracers in an Experimental Model of Pulmonary Tuberculosis
Authors
M. A. Stammes
M. P. M. Vierboom
C. C. Sombroek
J. Bakker
L. Meijer
R. A. W. Vervenne
S. O. Hofman
E. Nutma
I. Kondova
A. D. Windhorst
J. A. M. Langermans
F. A. W. Verreck
Publication date
21-10-2025
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 6/2025
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-025-02057-6
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

1.75 AMA PRA Category 1 Credits

Explore using biomarker testing to interpret results and guide treatment strategies through an interactive patient simulation and unique educational escape rooms.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more
Image Credits
Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME